Current review of small molecule ret kinase inhibitors

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 138-146

  Zuercher, W J ^a   Turunen, B J ^a   Lackey, K E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Protein tyrosine kinase inhibitors; Ret kinase; Thyroid cancer

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL) PYRAZOLO [3, 4 D] PYRIMIDINE; 5 [(5 FLUORO 1, 2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE) METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2, 4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; 5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL) PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO [2, 3 D] PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AST 487; CHIR 265; DOVITINIB; LINIFANIB; MIDOSTAURIN; MOTESANIB; PAZOPANIB; PROTEIN INHIBITOR; PROTEIN RET; RET KINASE INHIBITOR; SEMAXANIB; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TIPIFARNIB; TOZASERTIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG TARGETING; HUMAN; IC 50; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET;

EID: 77954704445     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955710791185154     Document Type: Review

References (45)

1. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9, 28-39.
2. Golden, J. P.; DeMaro, J. A.; Osborne, P. A.; Milbrandt, J.; Johnson, E. M., Jr. Expression of neurturin, GDNF, and GDNF familyreceptor mRNA in the developing and mature mouse. Exp. Neurol., 1999, 158, 504-528.
3. Salomon R; Attie T; Amiel J; Pelet A; Niaudet P; Lyonnet S RET proto-oncogene: role in kidney development and molecular pathology. Adv.Nephrol. Necker Hosp., 2008, 28, 401-417.
4. Taraviras, S.; Marcos-Gutierrez, C. V.; Durbec, P.; Jani, H.; Grigoriou, M.; Sukumaran, M.; Wang, L. C.; Hynes, M.; Raisman, G.; Pachnis, V. Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Development, 1999, 126, 2785-2797.
5. Viglietto, G.; Chiappetta, G.; Martinez-Tello, F. J.; Fukunaga, F. H.; Tallini, G.; Rigopoulou, D.; Visconti, R.; Mastro, A.; Santoro, M.; Fusco, A. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene, 1995, 11, 1207-1210.
6. Jurvansuu, J. M.; Goldman, A. Recent Inventions on Receptor Tyrosine Kinase RET Modulation. Recent Pat. Biotechnol., 2008, 2, 47-54.
7. Lanzi, C.; Cassinelli, G.; Cuccuru, G.; Zunino, F. Targeting RET for Thyroid Cancer Treatment. Leading Edge Cancer Research, 2007, 35-64.
8. Wilhelm, S. M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J. M.; Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7, 3129-3140.
9. Yao, J. C.; Zhang, J. X.; Rashid, A.; Yeung, S. C.; Szklaruk, J.; Hess, K.; Xie, K.; Ellis, L.; Abbruzzese, J. L.; Ajani, J. A. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin. Cancer Res., 2007, 13, 234-240.
10. Robinett, R. G.; Freemerman, A. J.; Skinner, M. A.; Shewchuk, L.; Lackey, K. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 5886-5893.
11. Knowles, P. P.; Murray-Rust, J.; Kjaer, S.; Scott, R. P.; Hanrahan, S.; Santoro, M.; Ibanez, C. F.; McDonald, N. Q. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem., 2006, 281, 33577-33587.
12. Cincinelli, R.; Cassinelli, G.; Dallavalle, S.; Lanzi, C.; Merlini, L.; Botta, M.; Tuccinardi, T.; Martinelli, A.; Penco, S.; Zunino, F. Synthesis, modeling, and RET protein kinase inhibitory activity of 3-and 4-substituted beta-carbolin-1-ones. J. Med. Chem., 2008, 51, 7777-7787.
13. Chiu, G.; Li, S.; Connolly, P. J.; Middleton, S. A.; Emanuel, S. L.; Huang, S.; Lin, R.; Lu, Y. 3-(Benzimidazolyl)-pyrazolopyridines as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. PCT Int. Appl. WO 2006130673, 2006.
14. Berdini, V.; Curry, J. E.; Gallagher, N. J.; Gill, A. L.; Lyons, J. F. Aminopyrazolylbenzimidazole derivatives and their preparation, pharmaceutical compositions and use in the treatment of kinasemediated diseases. PCT Int. Appl. WO 2007077435, 2007.
15. Fancelli, D.; Moll, J.; Varasi, M.; Bravo, R.; Artico, R.; Berta, D.; Bindi, S.; Cameron, A.; Candiani, I.; Cappella, P.; Carpinelli, P.; Croci, W.; Forte, B.; Giorgini, M. L.; Klapwijk, J.; Marsiglio, A.; Pesenti, E.; Rocchetti, M.; Roletto, F.; Severino, D.; Soncini, C.; Storici, P.; Tonani, R.; Zugnoni, P.; Vianello, P. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem.,2006, 49, 7247-51.
16. Binch, H.; Mortimore, M.; Fraysse, D.; Rutherford, A. Aminopyrimidines as Aurora protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. PCT Int. Appl. WO 2007056163, 2007.
17. Fagin, J. A. Method of treatment of thyroid cancer. PCT Int. Appl. WO 2003030908, 2003.
18. Ribas, J.; Bettayeb, K.; Ferandin, Y.; Knockaert, M.; Garrofe-Ochoa, X.; Totzke, F.; Schaechtele, C.; Mester, J.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A-L.; Boix, J.; Meijer, L. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death. Oncogene, 2006, 25, 6304-18.
19. Bold, G.; Caravatti, G.; Floersheimer, A.; Guagnano, V.; Imbach, P.; Masuya, K.; Roesel, J.; Vaupel, A.; Garcia-Echeverria, C. Diaryl urea derivatives, particularly N-[4-(pyrimidin-4-yloxy)phenyl]-N'-phenylureas, useful in the treatment of protein kinase dependent diseases, especially neoplasm, and their preparation. PCT Int. Appl. WO 2005051366, 2005.
20. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol., 2008, 26, 127-132.
21. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298, 1912-1934.
22. Glade-Bender, J.; Kandel, J. J.; Yamashiro, D. J. VEGF blocking therapy in the treatment of cancer. Expert. Opin. Biol. Ther., 2003, 3, 263-276.
23. Mologni, L.; Sala, E.; Cazzaniga, S.; Rostagno, R.; Kuoni, T.; Puttini, M.; Bain, J.; Cleris, L.; Redaelli, S.; Riva, B.; Formelli, F.; Scapozza, L.; Gambacorti-Passerini, C. Inhibition of RET tyrosine kinase by SU5416. J. Mol. Endocrinol., 2006, 37, 199-212.
24. Kim, D. W.; Jo, Y. S.; Jung, H. S.; Chung, H. K.; Song, J. H.; Park, K. C.; Park, S. H.; Hwang, J. H.; Rha, S. Y.; Kweon, G. R.; Lee, S. J.; Jo, K. W.; Shong, M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab., 2006, 91, 4070-4076.
25. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 2003, 9, 327-337.
26. Kim, D. W.; Jo, Y. S.; Jung, H. S.; Chung, H. K.; Song, J. H.; Park, K. C.; Park, S. H.; Hwang, J. H.; Rha, S. Y.; Kweon, G. R.; Lee, S. J.; Jo, K. W.; Shong, M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab., 2006, 91, 4070-4076.
27. Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J. P.; Scigalla, P.; Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol., 2006, 24, 25-35.
28. Sathornsumetee, S.; Rich, J. N. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc.), 2006, 42, 657-670.
29. McCarty, M. F.; Wey, J.; Stoeltzing, O.; Liu, W.; Fan, F.; Bucana, C.; Mansfield, P. F.; Ryan, A. J.; Ellis, L. M. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol. Cancer Ther., 2004, 3, 1041-1048.
30. Ryan, A. J.; Wedge, S. R. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer, 2005, 92 Suppl 1, S6-13.
31. Vidal, M.; Wells, S.; Ryan, A.; Cagan, R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res., 2005, 65, 3538-3541.
32. Wells, S.; You, Y. N.; Lakhani, V.; Hou, J.; Langmuir, P.; Headley, D.; Skinner, M.; Morse, M.; Burch, W.; Schlumberger, M. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I., 2006, 24, 5533.
33. Tyler, R. K.; Shpiro, N.; Marquez, R.; Eyers, P. A. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle, 2007, 6, 2846-2854.
34. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Jose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med., 2004, 10, 262-267.
35. Wang, Y.; Serradell, N. VX-680/MK-0457 aurora kinase inhibitor oncolytic. Drugs Future, 2008, 32, 144-147.
36. Buser-Doepner, C. A.; Freedman, S. J.; Pickett, C. A. Pyrimidine derivative for RET tyrosine kinase inhibition, and use for the treatment of thyroid cancer. PCT Int. Appl. WO 2007087245, 2007.
37. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res., 2004, 64, 4931-4941.
38. Croyle, M.; Akeno, N.; Knauf, J. A.; Fabbro, D.; Chen, X.; Baumgartner, J. E.; Lane, H. A.; Fagin, J. A. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res., 2008, 68, 4183-4191.
39. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109.
40. Plaza-Menacho, I.; Mologni, L.; Sala, E.; Gambacorti-Passerini, C.; Magee, A. I.; Links, T. P.; Hofstra, R. M.; Barford, D.; Isacke, C. M. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J. Biol. Chem., 2007, 282, 29230-29240.
41. Lierman, E.; Folens, C.; Stover, E. H.; Mentens, N.; Van, M. H.; Scheers, W.; Boogaerts, M.; Vandenberghe, P.; Marynen, P.; Cools, J. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood, 2006, 108, 1374-1376.
42. Hong, D.; Ye, L.; Gagel, R.; Chintala, L.; El Naggar, A. K.; Wright, J.; Kurzrock, R. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol. Cancer Ther., 2008, 7, 1001-1006.
43. Lobell, R. B.; Omer, C. A.; Abrams, M. T.; Bhimnathwala, H. G.; Brucker, M. J.; Buser, C. A.; Davide, J. P.; deSolms, S. J.; Dinsmore, C. J.; Ellis-Hutchings, M. S.; Kral, A. M.; Liu, D.; Lumma, W. C.; Machotka, S. V.; Rands, E.; Williams, T. M.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Heimbrook, D. C.; Kohl, N. E. Evaluation of farnesyl:protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res., 2001, 61, 8758-8768.
44. Brunner, T. B.; Hahn, S. M.; Gupta, A. K.; Muschel, R. J.; McKenna, W. G.; Bernhard, E. J. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res., 2003, 63, 5656-5668.
45. Ludwig, L.; Kessler, H.; Wagner, M.; Hoang-Vu, C.; Dralle, H.; Adler, G.; Bohm, B. O.; Schmid, R. M. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RETinduced transformation. Cancer Res., 2001, 61, 4526-4535.